Received Jul 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | IM |
a small rash with no open lesions across his back at the belt line; This non-serious case was reported by a consumer via call center representative and described the occurrence of rash in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On 24-APR-2025, the patient received the 1st dose of Shingrix (intramuscular). On 27-JUN-2025, 64 days after receiving Shingrix, the patient experienced rash (Verbatim: a small rash with no open lesions across his back at the belt line). The outcome of the rash was not resolved. It was unknown if the reporter considered the rash to be related to Shingrix. It was unknown if the company considered the rash to be related to Shingrix. Additional Information: GSK Receipt Date: 01-JUL-2025 The patient called to ask if he should receive his 2nd dose of Shingrix. He described a small rash with no open lesions across his back at the belt line. It crosses the midline. This report was being submitted with minimal information. No additional information is known.